168 related articles for article (PubMed ID: 8562903)
1. Targeting diphtheria toxin to growth factor receptors.
Murphy JR; vanderSpek JC
Semin Cancer Biol; 1995 Oct; 6(5):259-67. PubMed ID: 8562903
[TBL] [Abstract][Full Text] [Related]
2. Recombinant fusion toxins--a new class of targeted biologic therapeutics.
Woodworth TG; Nichols JC
Cancer Treat Res; 1993; 68():145-60. PubMed ID: 8105849
[TBL] [Abstract][Full Text] [Related]
3. Protein engineering of diphtheria toxin. Development of receptor-specific cytotoxic agents for the treatment of human disease.
Murphy JR; Lakkis FG; vanderSpek JC; Anderson P; Strom TB
Targeted Diagn Ther; 1992; 7():365-82. PubMed ID: 1633299
[No Abstract] [Full Text] [Related]
4. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.
Nichols J; Foss F; Kuzel TM; LeMaistre CF; Platanias L; Ratain MJ; Rook A; Saleh M; Schwartz G
Eur J Cancer; 1997 Jan; 33 Suppl 1():S34-6. PubMed ID: 9166099
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy.
Tepler I; Schwartz G; Parker K; Charette J; Kadin ME; Woodworth TG; Schnipper LE
Cancer; 1994 Feb; 73(4):1276-85. PubMed ID: 8313331
[TBL] [Abstract][Full Text] [Related]
6. Epitope tagging of DAB389IL-2: new insights into C-domain delivery to the cytosol of target cells.
van der Spek J; Hémard A; Dautry-Varsat A; Boquet P; Murphy JR
Leukemia; 1994 Apr; 8 Suppl 1():S144-8. PubMed ID: 7512176
[TBL] [Abstract][Full Text] [Related]
7. Genetic assembly and selective toxicity of diphtheria-toxin-related polypeptide hormone fusion proteins.
Murphy JR; Bishai W; Williams D; Bacha P; Borowski M; Parker K; Boyd J; Waters C; Strom TB
Biochem Soc Symp; 1987; 53():9-23. PubMed ID: 2847744
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2 receptor-directed therapies: antibody-or cytokine-based targeting molecules.
Strom TB; Kelley VR; Murphy JR; Nichols J; Woodworth TG
Annu Rev Med; 1993; 44():343-53. PubMed ID: 8476255
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.
Foss FM
Ann N Y Acad Sci; 2001 Sep; 941():166-76. PubMed ID: 11594570
[TBL] [Abstract][Full Text] [Related]
10. The effects of helix breaking mutations in the diphtheria toxin transmembrane domain helix layers of the fusion toxin DAB389IL-2.
Hu HY; Huynh PD; Murphy JR; vanderSpek JC
Protein Eng; 1998 Sep; 11(9):811-7. PubMed ID: 9796831
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor.
LeMaistre CF; Meneghetti C; Rosenblum M; Reuben J; Parker K; Shaw J; Deisseroth A; Woodworth T; Parkinson DR
Blood; 1992 May; 79(10):2547-54. PubMed ID: 1586707
[TBL] [Abstract][Full Text] [Related]
12. DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology.
Foss FM
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S27-31. PubMed ID: 11707860
[TBL] [Abstract][Full Text] [Related]
13. Diphtheria toxin-based receptor-specific chimaeric toxins as targeted therapies.
Sweeney EB; Murphy JR
Essays Biochem; 1995; 30():119-31. PubMed ID: 8822152
[TBL] [Abstract][Full Text] [Related]
14. Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells.
Waters CA; Schimke PA; Snider CE; Itoh K; Smith KA; Nichols JC; Strom TB; Murphy JR
Eur J Immunol; 1990 Apr; 20(4):785-91. PubMed ID: 2140788
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia.
LeMaistre CF; Rosenblum MG; Reuben JM; Parkinson DR; Meneghetti CM; Parker K; Shaw JP; Deisseroth AB; Woodworth T
Lancet; 1991 May; 337(8750):1124-5. PubMed ID: 1674015
[TBL] [Abstract][Full Text] [Related]
16. Structure/function analysis of the transmembrane domain of DAB389-interleukin-2, an interleukin-2 receptor-targeted fusion toxin. The amphipathic helical region of the transmembrane domain is essential for the efficient delivery of the catalytic domain to the cytosol of target cells.
vanderSpek JC; Mindell JA; Finkelstein A; Murphy JR
J Biol Chem; 1993 Jun; 268(16):12077-82. PubMed ID: 8505330
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 2 toxin: a step toward selective immunomodulation.
Murphy JR; Kelley VE; Strom TB
Am J Kidney Dis; 1988 Feb; 11(2):159-62. PubMed ID: 3124610
[TBL] [Abstract][Full Text] [Related]
18. DAB486IL-2 fusion toxin in refractory rheumatoid arthritis.
Sewell KL; Parker KC; Woodworth TG; Reuben J; Swartz W; Trentham DE
Arthritis Rheum; 1993 Sep; 36(9):1223-33. PubMed ID: 8216416
[TBL] [Abstract][Full Text] [Related]
19. Targeting the epidermal growth factor receptor in breast cancer cell lines with a recombinant ligand fusion toxin (DAB389EGF).
Osborne CK; Coronado-Heinsohn E
Cancer J Sci Am; 1996; 2(3):175-80. PubMed ID: 9166518
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.
Platanias LC; Ratain MJ; O'Brien S; Larson RA; Vardiman JW; Shaw JP; Williams SF; Baron JM; Parker K; Woodworth TG
Leuk Lymphoma; 1994 Jul; 14(3-4):257-62. PubMed ID: 7950914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
